No benefit for diabetes drug in pancreatic cancer, preclinical study finds

The diabetes drug metformin failed to show any benefit against pancreatic cancer, despite excitement about the drug for its potential anti-cancer benefits, report scientists. They believe the study underscores the importance of testing new therapies in preclinical animal models that incorporate actual tumor tissue to predict patient response.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1nEeOEz